Collaboration and Licensing Agreements - Narrative (Details) $ in Thousands, $ in Millions, ¥ in Billions	1 Months Ended			12 Months Ended				86 Months Ended
	Dec. 31, 2017 USD ($)	Nov. 30, 2017 USD ($)	Jun. 30, 2015 USD ($)	Dec. 31, 2024 USD ($) payment_tranche	Dec. 31, 2024 CAD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2024 USD ($) payment_tranche	Dec. 31, 2024 JPY (¥) payment_tranche	Apr. 30, 2023 USD ($)	Mar. 31, 2018 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues				$ 333,615		$ 124,456	$ 52,158
Licensing revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues				78		35,809	35,031
Kyowa Kirin | 2017 KKC Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront license fees		$ 30,000
Potential development milestones		$ 55,000
Total revenues								$ 35,000
Potential commercialization milestones				$ 54,000				54,000	¥ 8.5
Period to reduce royalty rate				2 years	2 years
Fee receivable for reduction in royalty rate				$ 40,000				$ 40,000
Number of payment tranches for fee receivable for reduction in royalty rate | payment_tranche				2				2	2
Kyowa Kirin | 2017 KKC Agreement | Licensing revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues				$ 0		30,000	35,000
Fosun Pharma | Fosun Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payment received	$ 12,000
Potential development and commercialization milestones				113,000
Proceeds from milestone payments				$ 8,000				$ 8,000
Threshold percentage of net sales for tiered royalties				20.00%	20.00%
Fosun Pharma | Fosun Agreement | Licensing revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues				$ 0		5,000	0
Knight | Knight Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential development milestones				700				700
Potential development and commercialization milestones				15,400	$ 22.2
Upfront payment											$ 2,300
Knight | Knight Agreement | Licensing revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues				78		59	31
AstraZeneca | AZ Termination Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of royalty revenue			10.00%
Percentage of non royalty revenue			20.00%
Maximum potential payment per agreement			$ 75,000
Aggregate cost of revenue recognized				62,300				$ 62,300
Cost of revenue				34,700		12,400	3,600
METiS Therapeutics Inc | Licensing revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues				$ 0		$ 750	$ 0
Proceeds from milestone payments										$ 243,000
Upfront payment										$ 800